Viamet Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Viamet Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10838
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Viamet Pharmaceuticals Inc (Viamet), a subsidiary of Viamet Pharmaceuticals Holdings LLC, discovers and develops novel medicinal drugs based on metalloenzyme chemistry and biology technology platform. Its product pipeline includes clinical-stage compounds such as VT-1161, an oral inhibitor used for the treatment of onychomycosis and recurrent vulvovaginal candidiasis; VT-1129, an oral agent for the treatment of cryptococcal meningitis; VT-1598, an oral inhibitor to treat invasive fungal infections, including coccidioidomycosis. The company’s proprietary MIDAS technology (Metalloenzyme Inhibitor Design and Synthesis) enables to discover metalloenzyme inhibitors that target fungal CYP51 of both chronic and life threatening fungal infections. Viamet is headquartered in Durham, North Carolina, the US.

Viamet Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Viamet Pharma Raises USD12 Million in Venture Financing 10
Viamet Pharma Raises USD60 Million in Series D Venture Financing 11
Viamet Pharma Raises US$10 Million In Series C1 Financing 12
Private Equity 13
NovaQuest Capital to Acquire Viamet Pharma 13
Partnerships 14
Viamet Pharma Enters into Agreement with MSGERC 14
Licensing Agreements 15
Innocrin Pharma Enters into Licensing Agreement with Viamet Pharma for Metallophile Technology 15
Equity Offering 16
Viamet Pharma Withdraws IPO 16
Viamet Pharmaceuticals Inc – Key Competitors 18
Viamet Pharmaceuticals Inc – Key Employees 19
Viamet Pharmaceuticals Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Viamet Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Viamet Pharma Raises USD12 Million in Venture Financing 10
Viamet Pharma Raises USD60 Million in Series D Venture Financing 11
Viamet Pharma Raises US$10 Million In Series C1 Financing 12
NovaQuest Capital to Acquire Viamet Pharma 13
Viamet Pharma Enters into Agreement with MSGERC 14
Innocrin Pharma Enters into Licensing Agreement with Viamet Pharma for Metallophile Technology 15
Viamet Pharma Withdraws IPO 16
Viamet Pharmaceuticals Inc, Key Competitors 18
Viamet Pharmaceuticals Inc, Key Employees 19
Viamet Pharmaceuticals Inc, Subsidiaries 20

List of Figures
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Viamet Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Scripps Research Institute:企業のM&A・提携動向(医療分野)
    Summary The Scripps Research Institute (TSRI) is a research and educational organization which conducts research in the areas of neurosciences, cardiovascular diseases, immunology, autoimmune diseases, chemistry, molecular and cellular biology, virology and synthetic vaccine development. The organiz …
  • Rubicon Minerals Corporation:企業の戦略・SWOT・財務情報
    Rubicon Minerals Corporation - Strategy, SWOT and Corporate Finance Report Summary Rubicon Minerals Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • DeepOcean Group Holding BV:企業の戦略的SWOT分析
    DeepOcean Group Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Accera, Inc.(製薬・医療分野):企業M&A動向
    Summary Accera, Inc. (Accera) is a biotechnology company. The company discovers and develops therapeutic drugs for the treatment of central nervous system disorders and other neurodegenerative diseases. Its products include Axona. The company’s product Axona is used in the treatment of Alzheimer's d …
  • Fagron NV (FAGR):企業のM&A・提携動向(医療機器分野)
    Summary Fagron NV (Fagron) formerly Arseus NV is a scientific pharmaceutical research and development company that provides pharmaceutical compounding solutions. The company provides compounding essentials, trademarks, and pharma services to pharmacies, hospitals and clinics. Its compounding service …
  • Dermalogica, Inc.(消費財分野):企業概要及びSWOT分析
    Product Synopsis Canadean's "Dermalogica, Inc.: Consumer Packaged Goods - Company Profile and SWOT Report" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description …
  • Merial Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Merial Ltd (Merial), a subsidiary of Boehringer Ingelheim GmbH, is an animal healthcare center that produces and markets pharmaceutical products and vaccines. The center offers products for dogs, cats, beef, dairy, equine, and swine to improve their health and performance. It develops specif …
  • Dunmore Corporation:企業の戦略的SWOT分析
    Dunmore Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Ostwind AG:企業のM&A・提携動向(エネルギー分野)
    Summary Ostwind AG (Ostwind) is a renewable energy company that develops, manages and constructs wind farms and solar projects. Its wind farms include Birgland, Blue columns line, Burns Mountain II, Oldrisov, Paintner Forestry, Tannberg Lindenhardt and Ursensollen. The company produces solar energy …
  • SkyFuel, Inc.:企業のM&A・提携動向(発電分野)
    Summary SkyFuel, Inc. (SkyFuel) is a renewable energy company that designs and manufactures parabolic through concentrating solar collectors. The company’s products include skytrough, reflectech, onsun and skytrakker. It offers maintenance services. SkyFuel supplies heat or steam to other thermal po …
  • Essendant Inc.:企業の戦略・SWOT・財務分析
    Essendant Inc. - Strategy, SWOT and Corporate Finance Report Summary Essendant Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Bharat Forge Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Bharat Forge Limited Mergers an …
  • Relentless Resources Ltd. (RRL):企業財務及び戦略的SWOT分析
    Summary Relentless Resources Ltd. (RRL), formerly New Range Resources Ltd. is an oil and gas company that acquires, develops, explores, and produces crude oil and natural gas in Alberta and Saskatchewan. The company’s properties include Willesden Green, Heathdale, Niton and Loverna. It also holds as …
  • Nippon Systemware Co., Ltd. (9739):企業の財務及び戦略的SWOT分析
    Summary Nippon Systemware Co., Ltd. (NSW) is a technology service provider that provides services such as software development, device development, system integration, and cloud services. The company’s consulting services include system integration, design, development, maintenance, outsourcing serv …
  • Lightsource Renewable Energy Limited:企業のM&A・提携動向(エネルギー分野)
    Summary Lightsource Renewable Energy Limited (Lightsource) is a solar energy generation company that carries out the development and operation of utility scale solar photovoltaic assets. The company focuses on providing fully funded solar photovoltaic solutions for commercial businesses and landowne …
  • Hua Eng Wire & Cable Co., Ltd. (1608):企業の財務及び戦略的SWOT分析
    Summary Hua Eng Wire & Cable Co., Ltd. (HEW&C), formerly Hua Eng copper and Iron Industrial Co., Ltd. is an electrical equipment company that manufactures wires and cables. The company offers products such as oxygen-free copper wire, aluminum wire (AAC), aluminum conductor, coated-steel reinforced ( …
  • EBTEC Corporation:企業の戦略・SWOT・財務分析
    SummaryEBTEC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • Abu Dhabi National Oil Company:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Abu Dhabi National Oil Company …
  • Astellas Pharma Europe Ltd.(製薬・医療分野):企業M&A動向
    Summary Astellas Pharma Europe Ltd. (Astellas Europe), a subsidiary of Astellas Pharma Inc. is a pharmaceutical company. The company researches discovers and develops new pharmaceutical products for the healthcare markets. It offers products for treatment in the therapeutic areas such as oncology, t …
  • Allianz Malaysia Berhad:企業の戦略・SWOT・財務分析
    SummaryAllianz Malaysia Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆